Fortune Small Business Lists Meridian Bioscience as One of America's Fastest-Growing Small Companies
CINCINNATI, June 25, 2008 (PRIME NEWSWIRE) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that FORTUNE Small Business has ranked Meridian Bioscience, Inc. number 65 on its eighth annual FSB 100 list of the fastest-growing small public companies in America. The list appears in the July/August issue of FORTUNE Small Business and is available online at http://money.cnn.com/magazines/fsb/fsb100/2008/
John A. Kraeutler, Chief Executive Officer, stated, The development, manufacture and distribution of rapid diagnostic tests and related biological components is the core growth strategy of Meridian Bioscience. We sincerely appreciate this recognition by FORTUNE Small Business of our ability to grow and add shareholder value. We will continue to offer novel products that can assist labs and physicians in the diagnosis and treatment of disease. We thank FORTUNE Small Business for this honor and, we thank our employees and customers for their loyalty and support.
To compile the eighth annual list, FORTUNE Small Business asked financial research firm Zacks to rank public companies with revenues less than $200 million and a stock price of more than $1, based on their percentage growth in earnings, revenue, and stock performance over the past three years.
Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com
CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, CEO